Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
== Medical relevance == Pseudouridine exerts a subtle but significant influence on the nearby sugar-phosphate backbone and also enhances base stacking. These effects may underlie the biological role of most – but perhaps not all – of the pseudouridine residues in RNA. Certain genetic mutants lacking specific pseudouridine residues in tRNA or rRNA exhibit difficulties in translation, display slow growth rates, and fail to compete effectively with wild-type strains in mixed culture. Pseudouridine modifications are also implicated in human diseases such as mitochondrial myopathy and sideroblastic anemia (MLASA) and Dyskeratosis congenita. Dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome are two rare inherited syndromes caused by mutations in DKC1, the gene encoding for the pseudouridine synthase dyskerin. Pseudouridines have been recognized as regulators of viral latency processes in human immunodeficiency virus (HIV) infections. Pseudouridylation has also been associated with the pathogenesis of maternally inherited diabetes and deafness (MIDD). In particular, a point mutation in a mitochondrial tRNA seems to prevent the pseudouridylation of one nucleotide, thus altering the tRNA tertiary structure. This may lead to higher tRNA instability, causing deficiencies in mitochondrial translation and respiration.
Analytical chemistry has applications across science and industry. It is fundamental to forensic science (e.g., DNA fingerprinting and toxicology), bioanalysis (e.g., measuring drug concentrations in pharmacokinetic studies), clinical analysis (e.g., blood glucose monitoring and COVID-19 PCR testing), environmental monitoring (e.g., testing for pollutants in water and air), and materials science (e.g., quality control of semiconductors and nanomaterials). Great effort is being put into shrinking the analysis techniques to chip size. Although few examples of such systems compete with traditional analysis techniques, potential advantages include size/portability, speed, and cost. Micro total analysis system (μTAS) or lab-on-a-chip. Microscale chemistry reduces the amount of chemicals used. Many developments improve the analysis of biological systems. Examples of rapidly expanding fields in this area are genomics, DNA sequencing and related research in genetic fingerprinting and DNA microarray; proteomics, the analysis of protein concentrations and modifications, especially in response to various stressors, at various developmental stages, or in various parts of the body; metabolomics, which deals with metabolites; transcriptomics, including mRNA and associated fields; lipidomics, dealing with lipids and its related fields; peptidomics, dealing with peptides and its related fields; and metallomics, dealing with metal concentrations and especially with their binding to proteins and other molecules.
They proposed a formation theory accounting for the dependence of microstructure on anodising conditions, and demonstrated the formation of porous gallium arsenide — the first porous III–V semiconductor — confirming the generality of the mechanism. In 1986, the same group also demonstrated that chemical stain etching produces porous silicon identical in structure to that formed by anodisation, unifying the two formation routes. This work on the formation mechanism and microstructure provided the basis for much of the subsequent research into the material's properties and applications—in fields as diverse as optoelectronics and photonics, chemical and biological sensing, biomedicine and drug delivery, photovoltaics, energy storage and microelectromechanical systems—and the model continues to be cited as a standard reference for porous silicon formation. Despite the discovery of porous silicon in the 1950s and the elucidation of its formation mechanism in the mid-1980s, the material attracted little wider attention until the end of the decade, when its nanoscale structure—a network of nanometre-sized pores within a crystalline silicon skeleton—was recognised as the source of optical, electronic and surface properties quite different from those of bulk silicon, triggering the rapid growth of interest that established porous silicon as a versatile nanostructured material with applications across optoelectronics, sensing, biomedicine, photovoltaics, energy storage and microelectronics.
Sources: en.wikipedia.org
According to North Korea: A Country Study by Robert L. Worden, Marxism–Leninism was abandoned immediately after the start of de-Stalinization in the Soviet Union and has been totally replaced by Juche since at least 1974. Daniel Schwekendiek wrote that what made North Korean Marxism–Leninism distinct from that of China and the Soviet Union was that it incorporated national feelings and macro-historical elements in the socialist ideology, opting for its "own style of socialism". The major Korean elements are the emphasis on traditional Confucianism and the memory of the traumatic experience of Korea under Japanese rule as well as a focus on autobiographical features of Kim Il Sung as a guerrilla hero.
Gonadotropin receptors are embedded in the surface of the target cell membranes and coupled to the G-protein system. Signals triggered by binding to the receptor are relayed within the cells by the cyclic AMP second messenger system. Gonadotropins are released under the control of gonadotropin-releasing hormone (GnRH) from the arcuate nucleus and preoptic area of the hypothalamus. The gonads — testes and ovaries — are the primary target organs for LH and FSH. The gonadotropins affect multiple cell types and elicit multiple responses from the target organs. As a simplified generalization, LH stimulates the Leydig cells of the testes and the theca cells of the ovaries to produce testosterone (and indirectly estradiol), whereas FSH stimulates the spermatogenic tissue of the testes and the granulosa cells of ovarian follicles, as well as stimulating production of estrogen by the ovaries. Although gonadotropins are secreted in a pulsatile manner (as a result of pulsatile GnRH release), unlike the case of GnRH and GnRH agonists, constant/non-pulsatile activation of the gonadotropin receptors by the gonadotropins does not produce functional inhibition. This can be seen during the first 7–10 weeks of pregnancy, where constantly high and progressively-increasing levels of hCG circulate and mediate production of estrogen and progesterone by the corpus luteum until the placenta takes over the production of these hormones.
The monoclonal antibody infliximab is a mouse-human chimeric antibody to TNF-α. The FDA approved it in 1998, making it the first approved TNF inhibitor. Infliximab has shown significant success in treating both Crohn's disease and ulcerative colitis, but it is also approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
== Research == In addition to the injectable and nasal spray dosage forms of the salmon calcitonin, noninvasive oral formulations of the peptide are currently under clinical development. The short-half-life of this peptide in serum triggered several attempts to enhance plasma concentrations. The peptide is complexed with a macromolecule that acts as an absorption enhancer through the transcellular pathway and, additionally, protects the peptide from the harsh pH and enzymatic conditions of the GI tract. This complexation is weak, noncovalent and reversible and the drug remains chemically unmodified. After passage through the intestine, the delivery agent dissociates from the peptide. One of the extensively studied oral formulations is the disodium salts of 5-CNAC oral calcitonin. This novel oral platform in a number of clinical trials at different phases has demonstrated promising enhanced pharmacokinetic profile, high bioavailability, well-established safety and comparable efficacy to that of nasal calcitonin especially for treatment of postmenopausal bone loss.
Sources: en.wikipedia.org
=== Host immune response === Fibroblasts from different anatomical sites in the body express many genes that code for immune mediators and proteins. These mediators of immune response enable the cellular communication with hematopoietic immune cells. The immune activity of non-hematopoietic cells, such as fibroblasts, is referred to as "structural immunity". In order to facilitate a fast response to immunological challenges, fibroblasts encode crucial aspects of the structural cell immune response in the epigenome.
In the 12th century BCE, many Israelite settlements appeared in the central hill country of Canaan, which was formerly an open terrain. These settlements lacked evidence of pork consumption, compared to Philistine settlements, had four-room houses and lived by an egalitarian ethos, which was exemplified by the absence of elaborate tombs, governor's mansions, certain houses being bigger than others etc. They followed a mixed economy, which prioritized self-sufficiency, cultivation of crops, animal husbandry and small-scale craft production. New technologies such as terraced farming, silos for grain storage and cisterns for rainwater collection were simultaneously introduced. These settlements were built by inhabitants of the "general Southland" (i.e. modern Sinai and the southern parts of Israel and Jordan), who abandoned their pastoral-nomadic ways. Canaanites who lived outside the central hill country were tenuously identified as Danites, Asherites, Zebulunites, Issacharites, Naphtalites and Gadites. These inhabitants do not have a significant history of migration besides the Danites, who allegedly originate from the Sea Peoples, particularly the Dan(an)u. Nonetheless, they intermingled with the former nomads, due to socioeconomic and military factors. Their interest in Yahwism and its concern for the underprivileged was another factor. Possible allusions to this historical reality in the Hebrew Bible include the aforementioned tribes, except for Issachar and Zebulun, descending from Bilhah and Zilpah, who were viewed as "secondary additions" to Israel.
== Adverse effects == Side effects are mostly mild and similar to other adenovirus vector vaccines such as the Oxford-AstraZeneca and the Janssen vaccines. However, unlike the Oxford-AstraZeneca and Janssen vaccines evidence does not suggest a risk of vaccine-induced immune thrombotic thrombocytopenia. However, a report from Argentina published in the New England Journal of Medicine described fatal vaccine-induced thrombocytopenia and thrombosis in a young woman after receipt of Sputnik-V.
The first fully virtual court hearing of a capital case was made via Zoom on 23 April 2020, when the Court of Appeal acquitted 27-year-old Singaporean drug suspect Mohammad Azli Mohammad Salleh and dismissed both his drug charge and his death sentence. There were originally two executions scheduled for drug traffickers Syed Suhail bin Syed Zin and Mohd Fadzir bin Mustaffa on 18 September 2020 and 24 September 2020 respectively, but they were subsequently postponed due to stays of execution granted pending last-minute appeals against the death sentences. As a result, there was no one executed in 2020. Similarly between January and October 2021, no new execution dates were set for the inmates on Singapore's death row, due to the ongoing COVID-19 pandemic and resurgence of community cases. The execution of Nagaenthran K. Dharmalingam was supposed to be carried out on 10 November 2021, but it was postponed due to Nagaenthran contracting COVID-19. The suspension of Nagaenthran's execution in 2021 also led to no executions being carried out in 2021 itself. There were originally two executions of Roslan Bakar and Pausi Jefridin to be carried out on 16 February 2022 and a third execution of Rosman Abdullah on 23 February 2022 before they were postponed due to the men's appeals. Due to the increasing notices of executions being revealed publicly, there were lingering concerns from civil groups and international figures that Singapore might resume executions to accommodate the growing death row inmate population at Changi Prison.
== Further reading == Edwards, Clive A. (ed.) Earthworm Ecology. Boca Raton: CRC Press, 2004. Second revised edition. ISBN 0-8493-1819-X Lee, Keneth E. Earthworms: Their Ecology and Relationships with Soils and Land Use. Academic Press. Sydney, 1985. ISBN 0-12-440860-5 Stewart, Amy. The Earth Moved: On the Remarkable Achievements of Earthworms. Chapel Hill, N.C.: Algonquin Books, 2004. ISBN 1-56512-337-9
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.